• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在研究环境中招募精神分裂症患者的挑战与策略。

Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting.

机构信息

Jackson Memorial Hospital, Miami, Florida, USA.

New York State Psychiatric Institute, New York, USA.

出版信息

Int J Neuropsychopharmacol. 2022 Nov 17;25(11):924-932. doi: 10.1093/ijnp/pyac058.

DOI:10.1093/ijnp/pyac058
PMID:36037521
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9452184/
Abstract

BACKGROUND

With numerous potentially novel targets and pharmacodynamic biomarkers for schizophrenia entering late-stage testing, the next decade will bring an urgent need for well-conducted clinical trials. A critically important step for the successful execution of clinical research trials is timely and appropriate recruitment of participants. Patients with schizophrenia can be especially challenging to recruit because of the disability inherent in psychotic spectrum disorders. Research on how best to recruit for clinical trials is understudied. Clearly defining a model for recruitment procedures would be valuable for researchers and, by extension, the patient populations that may benefit from the insight gained by future clinical research.

METHODS

This article aims to offer suggestions for recruitment based on years of experience at the Columbia Schizophrenia Research Clinic (CSRC), a hub for clinical trials focusing on the etiology and treatment of various psychotic disorders.

RESULTS

The present report provides practical, step-by-step recommendations for implementing the highly effective CSRC recruitment model, including the benefits of 2 recruitment initiatives that were instituted in 2018: hiring a dedicated recruiter and targeted chart reviews at affiliated clinics. Other topics discussed include our umbrella protocol and database, advertising, and tips for collaborating with external sites.

CONCLUSIONS

Despite ongoing complications from coronavirus disease 2019, these strategies have been successful, increasing the rate of both consents and study enrollments by approximately 40% and enabling the CSRC to conduct multiple studies simultaneously.

摘要

背景

随着大量针对精神分裂症的潜在新型靶点和药效学生物标志物进入后期测试阶段,未来十年将迫切需要进行精心设计的临床试验。对于成功执行临床研究试验来说,一个至关重要的步骤是及时、适当地招募参与者。由于精神分裂症患者存在精神障碍,因此招募他们极具挑战性。对于如何最好地招募他们参加临床试验的研究还不够深入。明确一个招募程序模型对于研究人员来说将是非常有价值的,并且可以将从未来临床研究中获得的洞察力扩展到可能受益的患者群体。

方法

本文旨在根据哥伦比亚精神分裂症研究诊所(CSRC)多年的经验,为招募提供建议,该诊所是专注于各种精神障碍病因和治疗的临床试验中心。

结果

本报告提供了实施高效 CSRC 招募模型的实用、逐步的建议,包括 2018 年实施的 2 项招募计划的好处:聘请专门的招募人员和在附属诊所进行有针对性的图表审查。其他讨论的主题包括我们的总协议和数据库、广告以及与外部网站合作的技巧。

结论

尽管持续受到 2019 冠状病毒病的影响,但这些策略取得了成功,使同意率和研究入组率提高了约 40%,使 CSRC 能够同时进行多项研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c339/9670746/25a964a09bf0/pyac058f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c339/9670746/e278bd051555/pyac058f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c339/9670746/25a964a09bf0/pyac058f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c339/9670746/e278bd051555/pyac058f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c339/9670746/25a964a09bf0/pyac058f0002.jpg

相似文献

1
Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting.在研究环境中招募精神分裂症患者的挑战与策略。
Int J Neuropsychopharmacol. 2022 Nov 17;25(11):924-932. doi: 10.1093/ijnp/pyac058.
2
A description of the process of recruitment for research studies investigating the genetics of psychotic illness.对研究精神病性疾病遗传学的研究招募过程的描述。
Curr Psychiatry Rep. 2006 Aug;8(4):307-12. doi: 10.1007/s11920-006-0067-2.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Barriers and facilitators to recruitment in mental health services: care coordinators' expectations and experience of referring to a psychosis research trial.心理健康服务招募中的障碍与促进因素:护理协调员转介至精神病研究试验的期望与经验
Psychol Psychother. 2015 Sep;88(3):335-50. doi: 10.1111/papt.12042. Epub 2014 Sep 25.
5
Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.精准医疗,首次就诊:高度个性化和基于评估的青少年心理健康管理医疗模式。
Med J Aust. 2019 Nov;211 Suppl 9:S3-S46. doi: 10.5694/mja2.50383.
6
Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study.随机试验的招募:试验入组与参与策略研究。STEPS研究。
Health Technol Assess. 2007 Nov;11(48):iii, ix-105. doi: 10.3310/hta11480.
7
Overcoming recruitment barriers revealed high readiness to participate and low dropout rate among people with schizophrenia in a randomized controlled trial testing the effect of a Guided Self-Determination intervention.在一项测试引导式自主干预效果的随机对照试验中,克服招募障碍显示,精神分裂症患者参与意愿高且辍学率低。
BMC Psychiatry. 2014 Feb 3;14:28. doi: 10.1186/1471-244X-14-28.
8
Avatar Therapy for people with schizophrenia or related disorders.针对精神分裂症或相关障碍患者的阿凡达疗法。
Cochrane Database Syst Rev. 2020 May 8;5(5):CD011898. doi: 10.1002/14651858.CD011898.pub2.
9
Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials.比较诊所招募的参与者和 2 项远程 COVID-19 临床试验参与者在种族、民族和地理位置多样性方面的差异。
JAMA Netw Open. 2022 Feb 1;5(2):e2148325. doi: 10.1001/jamanetworkopen.2021.48325.
10
Special Issue: Psychosis from early intervention to treatment resistance.特刊:从早期干预到治疗抵抗的精神病
Ir J Psychol Med. 2019 Dec;36(4):239-241. doi: 10.1017/ipm.2019.40.

引用本文的文献

1
The Impact of Drug Delivery Systems on Pharmacokinetics and Drug-Drug Interactions in Neuropsychiatric Treatment.药物递送系统对神经精神疾病治疗中药代动力学和药物相互作用的影响。
Cureus. 2025 Jun 8;17(6):e85563. doi: 10.7759/cureus.85563. eCollection 2025 Jun.
2
Research assistants' experiences recruiting patients with psychosis into clinical trials: a qualitative study.研究助理招募精神病患者参与临床试验的经历:一项定性研究。
Trials. 2025 May 30;26(1):180. doi: 10.1186/s13063-025-08882-y.
3
Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research.

本文引用的文献

1
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.罗哌酮治疗精神分裂症阴性症状的疗效和安全性。
Schizophr Bull. 2022 May 7;48(3):609-619. doi: 10.1093/schbul/sbac013.
2
The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease.精神分裂症的谷氨酸/N-甲基-D-天冬氨酸受体(NMDAR)模型35年回顾:从综合征到疾病的历程
Schizophr Res. 2022 Apr;242:56-61. doi: 10.1016/j.schres.2022.01.013. Epub 2022 Feb 4.
3
Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.
知是成功的一半:精神分裂症研究中实现高效招募代表性样本的影响因素
Pharmaceut Med. 2025 Jan;39(1):29-38. doi: 10.1007/s40290-024-00545-8. Epub 2025 Jan 11.
4
Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.D-丝氨酸增强精神分裂症患者的学习能力与听觉及额叶产生的生物标志物有关:一项随机、双盲、安慰剂对照研究。
Res Sq. 2023 May 19:rs.3.rs-2943290. doi: 10.21203/rs.3.rs-2943290/v1.
5
Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.基于神经可塑性的听觉学习在精神分裂症中的剂量依赖性增强:NMDA 谷氨酸受体激动剂 D-丝氨酸的双盲、安慰剂对照、随机、靶向试验
Biol Psychiatry. 2023 Jul 15;94(2):164-173. doi: 10.1016/j.biopsych.2023.01.015. Epub 2023 Jan 28.
日常实践中不符合随机临床试验条件的精神分裂症患者的特征及结局
JAMA Psychiatry. 2022 Mar 1;79(3):210-218. doi: 10.1001/jamapsychiatry.2021.3990.
4
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.错配负波作为基于兴奋/抑制的治疗开发的靶点结合指标: 5-羟色胺 3 受体拮抗剂 CVN058 的双盲、安慰剂对照、随机、单剂量交叉研究
Neuropsychopharmacology. 2022 Feb;47(3):711-718. doi: 10.1038/s41386-021-01170-8. Epub 2021 Oct 20.
5
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.追踪胺相关受体 1 作为开发新型抗精神病药物的靶点:研究现状和未来方向。
CNS Drugs. 2021 Nov;35(11):1153-1161. doi: 10.1007/s40263-021-00864-3. Epub 2021 Oct 15.
6
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.多巴胺 D1 受体刺激作为精神分裂症的一种潜在认知目标机制。
Schizophr Bull. 2022 Jan 21;48(1):199-210. doi: 10.1093/schbul/sbab095.
7
How do participants in clinical trials compare with other patients with schizophrenia?参与临床试验的患者与其他精神分裂症患者相比情况如何?
Contemp Clin Trials Commun. 2021 Jun 15;22:100803. doi: 10.1016/j.conctc.2021.100803. eCollection 2021 Jun.
8
How do we address treating the negative symptoms of schizophrenia pharmacologically?我们如何从药理学角度治疗精神分裂症的阴性症状?
Expert Opin Pharmacother. 2021 Oct;22(14):1811-1813. doi: 10.1080/14656566.2021.1939677. Epub 2021 Jun 16.
9
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.超越多巴胺受体拮抗作用:精神分裂症治疗和预防的新靶点。
Int J Mol Sci. 2021 Apr 25;22(9):4467. doi: 10.3390/ijms22094467.
10
Perspectives of Trial Staff on the Barriers to Recruitment in a Digital Intervention for Psychosis and How to Work Around Them: Qualitative Study Within a Trial.试验人员对精神病数字干预招募障碍及应对方法的看法:一项试验中的定性研究
JMIR Hum Factors. 2021 Mar 5;8(1):e24055. doi: 10.2196/24055.